Digitalni repozitorij raziskovalnih organizacij Slovenije

Izpis gradiva
A+ | A- | SLO | ENG

Naslov:Napredovali MTC - izziv za zdravljenje
Avtorji:Bergant, Damijan (Avtor)
Jezik:Slovenski jezik
Tipologija:1.04 - Strokovni članek
Organizacija:Logo OI - Onkološki inštitut Ljubljana
Leto izida:2009
UDK:616-006
ISSN pri članku:1408-1741
OceCobissID:65324032 Povezava se odpre v novem oknu
URN:URN:NBN:SI:doc-B5E8Q06V
COBISS_ID:25707993 Povezava se odpre v novem oknu
Opombe:BSDOCID145268;
Število ogledov:1206
Število prenosov:276
Datoteke:.pdf PDF - Predstavitvena datoteka, prenos (136,71 KB)
 
Nadgradivo:Onkologija
Onkološki inštitut
 
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
Avtorske pravice:by Authors
:
  
Postavite miškin kazalec na naslov za izpis povzetka. Klik na naslov izpiše podrobnosti ali sproži prenos.


Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:31.08.2018

Sekundarni jezik

Jezik:Angleški jezik
Naslov:Advanced Medullary Thyroid Carcinoma – a Challenge for Multimodal Treatment (Case Presentation)
Povzetek:Medullary thyroid cancer is a rare, neuroendocrine, tumor. It arises from parafollicular or C-cells with the ability to produce and secrete different bioactive substances like calcitonin (TC) and CEA. MTC occurs as a sporadic tumor or in hereditary settings MEN 2A, MEN 2B and FMCT. Germ line point mutations in RET proto-oncogene are responsible for tumor rise and inheritance of settings. RET mutations diagnostics in MTC patients and their first degree relatives form the basis of genetic screening. Biological behavior of MTC shows great clinical variability. Surgery is still the treatment of choice for MTC while teleradiotherapy, chemotherapy and radioimmunotherapy are indicated in advanced disease. Molecularly targeted treatments are now part of clinical studies with some promising results. Status at admission is still the most important prognostic factor. Diagnostics, treatment - including molecularly targeted treatment and follow-up of 29-years-old patient with respiratory distress due to the advanced MTC is represented. In this case, inhibitors of receptor tyrosine kinases were used for the first time as a part of multimodal treatment of MTC at the Institute of Oncology (OI).

Arhiv

niGradiv

Nazaj